Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group

Lorenzo D'Ambrosio¹, Marta Sbaraglia², Alessandra Merlini³, Martina Rabino⁴, Giovanni Grignani⁵, Viviana Appolloni⁶, Giuseppe Badalamenti⁷, Giacomo Giulio Baldi⁸, Elena Bellan², Matteo Benelli⁹, Alexia Francesca Bertuzzi¹⁰, Roberto Biagini¹¹, Giuseppe Bianchi¹², Antonella Boglione¹³, Antonella Brunello¹⁴, Domenico Andrea Campanacci¹⁵, Ferdinando Cananzi¹⁶, Paolo Giovanni Casali¹⁷, Beatrice Casini¹⁸, Marilena Cesari¹⁹, Benedetta Chiusole¹⁴, Camilla Cristalli²⁰, Alessandro De Vita²¹, Elena Di Blasi²², Franca Fagioli²³, Valentina Fausti²⁴, Virginia Ferraresi²⁵, Anna Maria Frezza²⁶, Elena Fumagalli²⁶, Marco Gambarotti²⁷, Claudia Giani¹⁷, Alessandro Gronchi²⁸, Massimiliano Grassi²⁹, Toni Ibrahim¹⁹, Andrei Ivanescu³⁰, Gianluca Ignazzi⁶, Lorena Incorvaia⁷, Alessandra Linari³¹, Roberto Luksch³², Andrea Marrari¹⁹, Alessandro Mazzocca³³, Giuseppe Maria Milano³⁴, Carlo Morosi³⁵, Margherita Nannini³⁶, Pierina Navarria³⁷, Elena Palassini²⁶, Emanuela Palmerini³⁸, Fiammetta Paloschi³⁹, Maria Abbondanza Pantaleo³⁶, Sandro Pasquali⁴⁰, Valeria Pavese⁴, Enrico Pozzo³⁷, Vittorio Quagliuolo⁴¹, Michela Quirino⁴², Roberta Sanfilippo²⁶, Federica Santoro³¹, Katia Scotlandi²⁰, Massimo Serra²⁷, Elisabetta Setola⁴³, Sabino Strippoli⁴⁴, Salvatore Tafuto⁴⁵, Elisa Tirtei²³, Silvia Vanni²¹, Bruno Vincenzi³³, Roberta Maestro⁴⁶, Angelo Paolo Dei Tos², Silvia Stacchiotti²⁶

Affiliations

¹ Department of Oncology, University of Torino, Regione Gonzole 10, Orbassano, TO 10043, Italy; AOU San Luigi Gonzaga, Regione Gonzole 10, Orbassano, TO 10043, Italy. Electronic address: lorenzo.dambrosio@unito.it.
² Department of Integrated Diagnostics, Azienda Ospedale-Università Padova, Via A.Gabelli, 61, Padova 35128, Italy; Department of Medicine, University of Padova School of Medicine, Via A.Gabelli, 61, Padova 35128, Italy.
³ Department of Oncology, University of Torino, Regione Gonzole 10, Orbassano, TO 10043, Italy; AOU San Luigi Gonzaga, Regione Gonzole 10, Orbassano, TO 10043, Italy. Electronic address: alessandra.merlini@unito.it.
⁴ Department of Oncology, University of Torino, Regione Gonzole 10, Orbassano, TO 10043, Italy; AOU San Luigi Gonzaga, Regione Gonzole 10, Orbassano, TO 10043, Italy.
⁵ Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Strada Provinciale 142, Km 3.95, Candiolo, TO 10060, Italy.
⁶ Italian Sarcoma Group, Via Vanzetti 5, Milano 20133, Italy.
⁷ Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Via Liborio Giuffrè 5, Palermo 90127, Italy.
⁸ Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Via Suor Niccolina Infermiera 20/22, Prato 59100, Italy.
⁹ University of Firenze, Piazza San Marco 4, Firenze 50121, Italy.
¹⁰ Medical Oncology Department, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI 20089, Italy.
¹¹ Oncology Orthopeadic Unit; IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, Rome 00144, Italy.
¹² Unit of 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, Bologna 40136, Italy.
¹³ Oncologia 2, Ospedale San Giovanni Bosco, piazza Donatori di Sangue, 3, Torino 10154, Italy.
¹⁴ Medical Oncology 1 Unit, Department of Medical Oncology, Istituto Oncologico Veneto IOV IRCCS, Via Gattamelata, 64, Padova 35128, Italy.
¹⁵ Department of Surgery, Azienda Ospedaliera Universitaria Careggi, Largo Brambilla 3, Firenze 50134, Italy; Department of Health Sciences, University of Firenze, Viale Pieraccini 6, Firenze 50139, Italy.
¹⁶ Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Via Manzoni 56, Rozzano, MI 20089, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, MI 20072, Italy.
¹⁷ Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy; University of Milano, Via Festa del Perdono 7, Milano 20122, Italy.
¹⁸ Department of Pathology, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, Rome 00144, Italy.
¹⁹ Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
²⁰ Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, Bologna 40136, Italy.
²¹ Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Piero Maroncelli 40, Meldola 47014, Italy.
²² Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
²³ Pediatric Onco-Hematology, Ospedale Infantile Regina Margherita & Departmento of Sciences of Public Health and Pediatrics, Univeristy of Torino, Piazza Polonia 94, Torino 10126, Italy.
²⁴ Terapie cellulari avanzate e tumori rari, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Piero Maroncelli 40, Meldola 47014, Italy.
²⁵ Department of Sarcomas and Rare Tumors Departmental Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, Rome 00144, Italy.
²⁶ Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
²⁷ Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, Bologna 40136, Italy.
²⁸ Department of Surgery, Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
²⁹ Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi, 10, Genova 16132, Italy.
³⁰ Associazione EHE Italia, Concorezzo, MB 20863, Italy.
³¹ Pathology Unit, Città della Salute e della Scienza di Torino, Corso Bramante 88, Torino 10126, Italy.
³² Pediatric Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
³³ Department of Medical Oncology, Policlinico Universitario Campus Bio-Medico and Università Campus Bio-Medico, via Álvaro del Portillo 200, Roma 00128, Italy.
³⁴ Division of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio 4, Roma 00165, Italy.
³⁵ Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
³⁶ Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Via Giuseppe Massarenti, 9, Bologna 40138, Italy.
³⁷ Department of Radiation Therapy, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI 20089, Italy.
³⁸ Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, Miami, FL 33136, USA; Miller School of Medicine, University of Miami, 1475 NW 12th Ave, Miami, FL 33136, USA.
³⁹ Fondazione Italiana GIST ETS, Via G Venezian 1, Milano 20133, Italy.
⁴⁰ Department of Surgery, Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy; Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giovanni Antonio Amadeo 42, Milano 20133, Italy.
⁴¹ Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Via Manzoni 56, Rozzano, MI 20089, Italy.
⁴² Medical Oncology, Policlinico Gemelli, Largo Agostino Gemelli 8, Roma 00136, Italy.
⁴³ Department of Medical Oncology, IRCCS Istituto Europeo Oncologia, Via Giuseppe Ripamonti 435, Milano 20141, Italy.
⁴⁴ Rare Tumors and Melanoma Unit, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari 70124, Italy.
⁴⁵ Department of Sarcomas and Rare Tumors, Istituto Nazionale Tumori - IRCCS, Fondazione "G.Pascale", Via Mariano Semmola 52, Napoli 80131, Italy.
⁴⁶ Unit of Oncogenetics and Functional Oncogenomics, IRCCS Centro di Riferimento Oncologico di Aviano, , Via Franco Gallini 2, Aviano, PN 33081, Italy.

PMID: 40998028
DOI: 10.1016/j.critrevonc.2025.104960

Free article

Review

Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group

Lorenzo D'Ambrosio et al. Crit Rev Oncol Hematol. 2025.

Free article

. 2025 Sep 23:216:104960.

doi: 10.1016/j.critrevonc.2025.104960. Online ahead of print.

Authors

Affiliations

¹ Department of Oncology, University of Torino, Regione Gonzole 10, Orbassano, TO 10043, Italy; AOU San Luigi Gonzaga, Regione Gonzole 10, Orbassano, TO 10043, Italy. Electronic address: lorenzo.dambrosio@unito.it.
² Department of Integrated Diagnostics, Azienda Ospedale-Università Padova, Via A.Gabelli, 61, Padova 35128, Italy; Department of Medicine, University of Padova School of Medicine, Via A.Gabelli, 61, Padova 35128, Italy.
³ Department of Oncology, University of Torino, Regione Gonzole 10, Orbassano, TO 10043, Italy; AOU San Luigi Gonzaga, Regione Gonzole 10, Orbassano, TO 10043, Italy. Electronic address: alessandra.merlini@unito.it.
⁴ Department of Oncology, University of Torino, Regione Gonzole 10, Orbassano, TO 10043, Italy; AOU San Luigi Gonzaga, Regione Gonzole 10, Orbassano, TO 10043, Italy.
⁵ Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Strada Provinciale 142, Km 3.95, Candiolo, TO 10060, Italy.
⁶ Italian Sarcoma Group, Via Vanzetti 5, Milano 20133, Italy.
⁷ Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Via Liborio Giuffrè 5, Palermo 90127, Italy.
⁸ Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Via Suor Niccolina Infermiera 20/22, Prato 59100, Italy.
⁹ University of Firenze, Piazza San Marco 4, Firenze 50121, Italy.
¹⁰ Medical Oncology Department, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI 20089, Italy.
¹¹ Oncology Orthopeadic Unit; IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, Rome 00144, Italy.
¹² Unit of 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, Bologna 40136, Italy.
¹³ Oncologia 2, Ospedale San Giovanni Bosco, piazza Donatori di Sangue, 3, Torino 10154, Italy.
¹⁴ Medical Oncology 1 Unit, Department of Medical Oncology, Istituto Oncologico Veneto IOV IRCCS, Via Gattamelata, 64, Padova 35128, Italy.
¹⁵ Department of Surgery, Azienda Ospedaliera Universitaria Careggi, Largo Brambilla 3, Firenze 50134, Italy; Department of Health Sciences, University of Firenze, Viale Pieraccini 6, Firenze 50139, Italy.
¹⁶ Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Via Manzoni 56, Rozzano, MI 20089, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, MI 20072, Italy.
¹⁷ Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy; University of Milano, Via Festa del Perdono 7, Milano 20122, Italy.
¹⁸ Department of Pathology, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, Rome 00144, Italy.
¹⁹ Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
²⁰ Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, Bologna 40136, Italy.
²¹ Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Piero Maroncelli 40, Meldola 47014, Italy.
²² Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
²³ Pediatric Onco-Hematology, Ospedale Infantile Regina Margherita & Departmento of Sciences of Public Health and Pediatrics, Univeristy of Torino, Piazza Polonia 94, Torino 10126, Italy.
²⁴ Terapie cellulari avanzate e tumori rari, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Piero Maroncelli 40, Meldola 47014, Italy.
²⁵ Department of Sarcomas and Rare Tumors Departmental Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, Rome 00144, Italy.
²⁶ Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
²⁷ Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, Bologna 40136, Italy.
²⁸ Department of Surgery, Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
²⁹ Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi, 10, Genova 16132, Italy.
³⁰ Associazione EHE Italia, Concorezzo, MB 20863, Italy.
³¹ Pathology Unit, Città della Salute e della Scienza di Torino, Corso Bramante 88, Torino 10126, Italy.
³² Pediatric Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
³³ Department of Medical Oncology, Policlinico Universitario Campus Bio-Medico and Università Campus Bio-Medico, via Álvaro del Portillo 200, Roma 00128, Italy.
³⁴ Division of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio 4, Roma 00165, Italy.
³⁵ Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy.
³⁶ Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Via Giuseppe Massarenti, 9, Bologna 40138, Italy.
³⁷ Department of Radiation Therapy, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI 20089, Italy.
³⁸ Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, Miami, FL 33136, USA; Miller School of Medicine, University of Miami, 1475 NW 12th Ave, Miami, FL 33136, USA.
³⁹ Fondazione Italiana GIST ETS, Via G Venezian 1, Milano 20133, Italy.
⁴⁰ Department of Surgery, Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milano 20133, Italy; Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giovanni Antonio Amadeo 42, Milano 20133, Italy.
⁴¹ Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Via Manzoni 56, Rozzano, MI 20089, Italy.
⁴² Medical Oncology, Policlinico Gemelli, Largo Agostino Gemelli 8, Roma 00136, Italy.
⁴³ Department of Medical Oncology, IRCCS Istituto Europeo Oncologia, Via Giuseppe Ripamonti 435, Milano 20141, Italy.
⁴⁴ Rare Tumors and Melanoma Unit, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari 70124, Italy.
⁴⁵ Department of Sarcomas and Rare Tumors, Istituto Nazionale Tumori - IRCCS, Fondazione "G.Pascale", Via Mariano Semmola 52, Napoli 80131, Italy.
⁴⁶ Unit of Oncogenetics and Functional Oncogenomics, IRCCS Centro di Riferimento Oncologico di Aviano, , Via Franco Gallini 2, Aviano, PN 33081, Italy.

PMID: 40998028
DOI: 10.1016/j.critrevonc.2025.104960

Abstract

Extended molecular profiling using massive parallel sequencing (MPS) technologies, commonly referred to as next-generation sequencing (NGS), has revolutionized cancer diagnosis and treatment, including in bone and soft tissue sarcomas (BSTS). This heterogeneous group of mesenchymal tumors presents a complex spectrum of genetic alterations, such as chromosomal rearrangements, point mutations, and copy number variations. Unlike carcinomas, where driver mutations are often well defined, the role of specific genomic signatures in dictating BSTS prognosis and therapy response remains to be fully elucidated. Despite its promise, the adoption of MPS/NGS in BSTS is limited by variability in testing access, turnaround times, specimen quality, costs, and data interpretation. Although identified alterations are often not yet directly targetable, they provide critical insights that can refine diagnosis, enable better patient stratification, and guide treatment strategies. To optimize the use of MPS/NGS in BSTS, harmonization and multidisciplinary collaboration within molecular tumor boards (MTBs) are essential. With this aim, the Italian Sarcoma Group ETS (ISG) convened a consensus meeting to establish best practices for integrating MPS/NGS into everyday clinical care. ISG experts developed ten consensus statements: the first five address the role of extended molecular profiling in BSTS diagnostics, while the others offer guidance on MPS/NGS use and interpretation when searching for potentially actionable targets in the treatment of advanced disease. Furthermore, collaboration with the National Rare Cancer Network to offer expert consultation and systematically correlate MPS/NGS findings with clinical outcomes for BSTS cases undergoing extended molecular profiling will be critical to advancing precision medicine in this field.

Keywords: Bone tumors; GIST; Massive parallel sequencing; Next generation sequencing; Sarcoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All authors reported no conflict of interest (COI) for the present work. Outside the submitted work the following authors reported potential COIs: The Author Lorenzo D’Ambrosio reports the following COIs: Advisory role: PSI CRO Italy, Boerhinger Ingelheim, GSK, Eisai Co Ltd, and AstraZeneca Meeting participation: PharmaMar, Gentili, and Amgen Inc The Author Alessandra Merlini reports the following COIs: Grant (institutional): PharmaMar The Author Giovanni Grignani reports the following COIs: Grants and personal fees from PharmaMar, grants from Novartis, and personal consulting fees from Lilly, Pfizer, Bayer, and Eisai. The Author Giacomo Giulio Baldi reports the following COI: Advisory role: Pharmamar, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dome, Deciphera Consulting fees: Eli Lilly, Pharmamar Honoraria: Pharmamar, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dome, Istituto Gentili Travel grants: Istituto Gentili, Pharmamar, Eli Lilly The Author Domenico Andrea Campanacci reports the following COI: Link Italia; Adler Ortho The Author Elena Fumagalli reports the following COI: Consulting or Advisory Role: Deciphera PharmaceuticalsResearch Funding: Deciphera Pharmaceuticals (Inst), Blueprint Medicines (Inst), Cogent Biosciences (Inst), IDRX, Inc. (Inst.), GlaxoSmithKline (Inst), Novartis (Inst), PharmaMar (Inst), Eisai (Inst), Lilly (Inst), Advenchen Laboratories (Inst), Epizyme Inc. (Inst), Karyopharm Therapeutics (Inst), SpringWorks Ther (Inst),Daiichi Sankyo (Inst), Boehringer Ingelheim (Inst), Rain Therapeutics (Inst), Foghorn Ther Inc (Inst), Hutchinson MediPharam Lt (Inst), InhibRx (Inst), Ayala Pharmaceuticals (Inst.), Eli Lilly (Inst.), Abbisko Therapeutics Co. Ltd. (Inst.), Immunome (Inst.), Syneos Health (Inst.) The Author Elena Palassini reports the following COI: Institutional: Advenchen; Blueprint; Boehringer Ingelheim; Deciphera; EISAI; Eli Lilly; Epizyme Inc.; Daiichi Sankyo; Foghorn; Glaxo Smith Kline; HUTCHMED; Inhibrix; Karyopharm; Novartis; PharmaMar; Rain Therapeutic; SpringWorks; Cogent Biosciences; Ayala Pharmaceuticals; Abbisko Therapeutics Co. Ltd.; Immunome; IDRX, Inc.; Syneos Health The Author Salvatore Tafuto reports the following COI: Consultation for Novartis, Esteve, Camurus, Deciphera, Boehringer, Gentili, Ipsen. The Author Silvia Stacchiotti reports the following COI: honoraria, consultancy or advisory role: Bayer, Boehringer, Daiichi Sankyo, Deciphera, Gentili, Glaxo Smith Kline, Ikena, Ipsen, NEC Oncoimmunity, Novartis, Pharmamar, Pharma Essentia, Rain Therapeutics, Regeneron, Servier. Institutional financial interests: Abbisko, Advenchen, Bayer, Boehringer, Daiichi Sankyo, Deciphera, Eisai, Epizyme, Foghorn, Glaxo Smith Kline, Hutchinson, Inhibrix, Ipsen, Karyopharm, Novartis, Pharmamar, RainThera, Springworks

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group

Affiliations

Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

LinkOut - more resources

Full Text Sources